Joint Panel Favors More Postmarketing Studies For Bayer’s Trasylol
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite the unanimous recommendation for additional pharmacovigilance for safety, the cardio-renal and drug safety committees vote against taking the product off the market.